Nyxoah appoints Daniel Wildman to its Board of Directors

(Boursier.com) — Nyxoah SA operates in the medical technology sector and focuses on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea Syndrome (OSAS). It announces today the appointment of Mr. Daniel Wildman as Independent Director within its Board of Directors

.

Mr. Wildman has over 40 years of experience in the medical device industry. He is currently Chairman of the Board of Progenerative Medical, Inc. and strategic advisor to several pharmaceutical and medical device companies. He is also a member of the Board of Directors of UroGen Pharma, Ltd.

Mr. Wildman has spent most of his career at Johnson & Johnson (“J&J”), where he led the digital surgery strategic initiative, J&J’s DuPuy Synthes Spine franchise and J&J’s Ethicon Biosurgery division. Prior to J&J, Mr. Wildman spent ten years at Boston Scientific Corporation, where he held various positions in sales, marketing, operations and strategic planning.

Robert Taub, Chairman of the Nyxoah Board, commented: “We are delighted to welcome Mr. Wildman to the Nyxoah Board. His wealth of experience and knowledge in the medical device industries and pharmaceuticals will be valuable as Nyxoah develops its R&D, clinical and commercial strategies.”

Mr. Wildman added, “I am very impressed with the patient-centered design of Nyxoah’s Genio Hypoglossal Nerve Stimulation System and the benefits it can offer people with obstructive sleep apnea. member of the Board of Directors, I look forward to working with Nyxoah’s leadership team to gain approval and launch Genio in the United States.”